Trump unveiled a phased tariff plan on imported generic medicines with a zero tariff for two years, a 100% levy in the third year, and 200% thereafter, aimed at onshoring generic drug production. A two-year window was provided for manufacturers to move production to the United States, with penalties for failing to establish domestic facilities during the transition. Tariffs on patented and branded drugs would remain unchanged, and the policy is framed as a national-security and supply-chain measure. The plan expands earlier efforts and references exemptions for generics during talks with brand-name manufacturers, with the status of exemptions for facilities under construction left unclear in several reports. Analysts highlighted potential impacts on India, a major supplier of generics to the U.S., while critics warned higher costs and disrupted global supply chains. The administration argued the policy would reduce U.S. dependence on foreign producers, though timing and exemption details remain unsettled.